Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

NCT04887025 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Lymphoma

Interventions

BIOLOGICAL: RGV004

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

[object Object]